| Literature DB >> 30232220 |
Jooske F van Lidth de Jeude1, Claudia N Spaan1, Bartolomeus J Meijer1, Wouter L Smit1, Tanya T D Soeratram1, Mattheus C B Wielenga1, B Florien Westendorp1, Amy S Lee2, Sander Meisner1, Jacqueline L M Vermeulen1, Manon E Wildenberg1, Gijs R van den Brink1, Vanesa Muncan1, Jarom Heijmans3,4.
Abstract
Deletion of endoplasmic reticulum resident chaperone Grp78 results in activation of the unfolded protein response and causes rapid depletion of the entire intestinal epithelium. Whether modest reduction of Grp78 may affect stem cell fate without compromising intestinal integrity remains unknown. Here, we employ a model of epithelial-specific, heterozygous Grp78 deletion by use of VillinCreERT2-Rosa26ZsGreen/LacZ-Grp78+/fl mice and organoids. We examine models of irradiation and tumorigenesis, both in vitro and in vivo Although we observed no phenotypic changes in Grp78 heterozygous mice, Grp78 heterozygous organoid growth was markedly reduced. Irradiation of Grp78 heterozygous mice resulted in less frequent regeneration of crypts compared with nonrecombined (wild-type) mice, exposing reduced capacity for self-renewal upon genotoxic insult. We crossed mice to Apc-mutant animals for adenoma studies and found that adenomagenesis in Apc heterozygous-Grp78 heterozygous mice was reduced compared with Apc heterozygous controls (1.43 vs. 3.33; P < 0.01). In conclusion, epithelium-specific Grp78 heterozygosity compromises epithelial fitness under conditions requiring expansive growth such as adenomagenesis or regeneration after γ-irradiation. These results suggest that Grp78 may be a therapeutic target in prevention of intestinal neoplasms without affecting normal tissue.Significance: Heterozygous disruption of chaperone protein Grp78 reduces tissue regeneration and expansive growth and protects from tumor formation without affecting intestinal homeostasis. Cancer Res; 78(21); 6098-106. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30232220 PMCID: PMC8272399 DOI: 10.1158/0008-5472.CAN-17-3600
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701